Akari Therapeutics, Plc (AKTX)

1.6180 -0.1520 (-8.73%) As of 02:29PM EDT. Market open.

Akari Therapeutics, Plc

22 Boston Wharf Road
Floor 7
Boston, MA 02210
United States
929 274 7510
https://www.akaritx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Rachelle Suzanne Jacques	President, CEO & Director	632.25k	N/A	1971
Ms. Melissa Bradford-Klug	Chief Operating Officer	N/A	N/A	1970
Dr. Miles Nunn	Chief Scientific Officer	N/A	N/A	1969
Dr. John F. Neylan III, M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1953

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Corporate governance

Akari Therapeutics, Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.